Kairos Pharma
KAPA

Kairos Pharma (KAPA) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
D. Boral CapitalMaintainedBuy$9.00Nov 19, 2025
D. Boral CapitalMaintainedBuy$9.00Nov 4, 2025
D. Boral CapitalMaintainedBuy$9.00Oct 20, 2025
D. Boral CapitalMaintainedBuy$9.00Oct 7, 2025
D. Boral CapitalMaintainedBuy$9.00Sep 19, 2025
D. Boral CapitalMaintainedBuy$9.00Jul 16, 2025
D. Boral CapitalMaintainedBuy$9.00Jun 4, 2025
D. Boral CapitalMaintainedBuy$9.00Apr 17, 2025
HC Wainwright & Co.Initiated CoverageBuy$12.00Apr 3, 2025
D. Boral CapitalMaintainedBuy$9.00Mar 31, 2025
Maxim GroupInitiated CoverageBuy$4.00Mar 27, 2025
D. Boral CapitalMaintainedBuy$9.00Mar 20, 2025
D. Boral CapitalMaintainedBuy$9.00Feb 26, 2025
D. Boral CapitalMaintainedBuy$9.00Feb 18, 2025
D. Boral CapitalMaintainedBuy$9.00Feb 12, 2025
D. Boral CapitalMaintainedBuy$9.00Jan 22, 2025
D. Boral CapitalMaintainedBuy$9.00Nov 14, 2024
EF HuttonInitiated CoverageBuy$9.00Oct 14, 2024

Frequently asked questions

  • What is the latest analyst rating on KAPA?

    On Nov 19, 2025, D. Boral Capital maintained Kairos Pharma at Buy with a price target of $9.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.